Remote video URL
Your peers have not rated this talk yet.
11-minute watch | Talk 4 of 8

EHA: Navigating CAR T in 2L DLBCL

How has CAR T changed the second-line DLBCL treatment landscape?

Dr Olalekan Oluwole
Vanderbilt University Medical Center, Nashville, Tennessee, USA

Dr Olalekan Oluwole, Vanderbilt University Medical Center, Nashville, Tennessee, USA, explores the data from ZUMA-7 and uncovers the latest advances of CAR T-cell therapy in R/R DLBCL treatment

Read more

Talks in this series

Interested in this topic?

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.